# Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension

> **NCT04686643** · PHASE3 · UNKNOWN · sponsor: **Ahn-Gook Pharmaceuticals Co.,Ltd** · enrollment: 306 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** AGSAVI
- **DRUG:** AGLS

## Key facts

- **NCT ID:** NCT04686643
- **Lead sponsor:** Ahn-Gook Pharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-01
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-05-01
- **Target enrollment:** 306 (ESTIMATED)
- **Last updated:** 2020-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04686643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04686643, "Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04686643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*